ImmuCell Corporation Cost of Revenue
ImmuCell Corporation (ICCC) reported Cost of Revenue of $4.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-13
- ImmuCell Corporation cost of revenue for the quarter ending 2026-06-30 was $4.75M, a 30.93% increase year-over-year.
- ImmuCell Corporation cost of revenue for the quarter ending 2026-03-31 was $5.70M, a 20.93% increase year-over-year.
- ImmuCell Corporation cost of revenue for the quarter ending 2025-12-31 was $4.72M, a 4.14% decline year-over-year.
- ImmuCell Corporation cost of revenue for the quarter ending 2025-09-30 was $3.14M, a 29.02% decline year-over-year.
- ImmuCell Corporation cost of revenue for fiscal 2025 was $16.20M, a 12.68% decline from fiscal 2024.
- ImmuCell Corporation cost of revenue for fiscal 2024 was $18.55M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.75M 10-Q · filed 2026-08-13 | $10.45M 10-Q · filed 2026-08-13 | $15.16M derived: sum of 3 quarters · filed 2026-08-13 | $18.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $5.70M 10-Q · filed 2026-05-14 | $10.42M derived: sum of 2 quarters · filed 2026-05-14 | $13.56M derived: sum of 3 quarters · filed 2026-05-14 | $17.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.86M derived: sum of 2 quarters · filed 2026-03-30 | $11.49M derived: sum of 3 quarters · filed 2026-08-13 | $16.20M 10-K · filed 2026-03-30 |
| 2025-09-30 | $3.14M 10-Q · filed 2025-11-13 | $6.77M derived: sum of 2 quarters · filed 2026-08-13 | $11.48M 10-Q · filed 2025-11-13 | $16.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.63M 10-Q · filed 2026-08-13 | $8.34M 10-Q · filed 2026-08-13 | $13.26M derived: sum of 3 quarters · filed 2026-08-13 | $17.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $4.71M 10-Q · filed 2026-05-14 | $9.63M derived: sum of 2 quarters · filed 2026-05-14 | $14.06M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $9.35M derived: sum of 2 quarters · filed 2026-03-30 | $18.55M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $4.43M 10-Q · filed 2025-11-13 | $13.63M 10-Q · filed 2025-11-13 | ||
| 2023-09-30 | $13.60M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |